**Core Concept**
Cyclophosphamide is a nitrogen mustard alkylating agent used in the treatment of various cancers, including lymphomas, leukemias, and solid tumors. Its mechanism of action involves cross-linking DNA strands, thereby inhibiting DNA replication and transcription. Additionally, cyclophosphamide has been used in the treatment of rheumatoid arthritis (RA) due to its immunosuppressive properties.

**Why the Correct Answer is Right**
Cyclophosphamide is metabolized to acrolein, a toxic byproduct, which is excreted in the urine. Acrolein is responsible for causing hemorrhagic cystitis, a condition characterized by bleeding from the bladder mucosa. This adverse effect is a significant concern in patients receiving cyclophosphamide, particularly those with prolonged or high-dose treatment. The use of mesna (sulfhydryl compound) has been shown to reduce the incidence of hemorrhagic cystitis by conjugating with acrolein and preventing its toxic effects.

**Why Each Wrong Option is Incorrect**
**Option B:** Busulfan is a nitrogen mustard alkylating agent, but it is primarily used in the treatment of chronic myeloid leukemia (CML). Busulfan does not produce acrolein as a metabolite and is not associated with hemorrhagic cystitis.

**Option C:** Procarbazine is an alkylating agent used in the treatment of Hodgkin's lymphoma and brain tumors. While procarbazine has various toxicities, it does not produce acrolein or cause hemorrhagic cystitis.

**Option D:** Mesna is a sulfhydryl compound used to prevent hemorrhagic cystitis caused by cyclophosphamide and ifosfamide. Mesna does not produce acrolein or cause hemorrhagic cystitis itself; instead, it is used to mitigate this adverse effect.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that patients receiving cyclophosphamide should be monitored for signs of hemorrhagic cystitis, such as hematuria, dysuria, and suprapubic pain. Early recognition and prompt treatment can help prevent severe complications.

**✓ Correct Answer: A. Cyclophosphamide**